Plaque AnalysisHelping You DECIDE What’s Right For Your Patients
The Largest Prospective Registry on Plaque Analysis in Coronary Artery Disease (CAD)
The DECIDE Registry is a landmark prospective study of ~22,000 patients at over 30 centers across the United States. DECIDE demonstrates how Heartflow Plaque Analysis with Plaque Staging* empowers physicians with clinical insights that lead to real-world impact. This is the next step in preventive CAD management, where diagnostic precision drives confident treatment planning.
What if 50% of your CCTA patients could benefit from an adjustment to their treatment plan?
Traditional risk factors, such as age, family history, smoking, or hypertension, are useful for predicting CAD in populations but fall short at the individual level.1,2 While CCTA alone is capable of visualizing plaque, conventional interpretation1-3 doesn’t provide plaque quantity by type, which is proven to be a more accurate predictor of cardiac events.3 Plaque Analysis identifies and quantifies all plaque types, providing you with personalized data and Plaque Staging* insights to determine which 50% of your patients require changes to their treatment plans.4
The DECIDE Registry demonstrates it.
The DECIDE Registry demonstrates it.
Plaque AnalysisInsights Built for Action in the DECIDE Registry
Medical management recommendations developed by preventive cardiology and CCTA expert consensus are being studied in the DECIDE Registry, the largest prospective registry on Plaque Analysis.4
Learn More About Plaque Staging*Why DECIDE Matters. The Outcomes4
More than
of patients had medical management changed after Plaque Analysis.
Nearly
of patients with CAC 0 had a change in management.
Around
expected decreased risk of cardiac events based on avg LDL-C decrease of 18.7 mg/dL.5
Patients had their medical management changed when Plaque Analysis with Plaque Staging* was added compared to their management based on CCTA alone.
Patients with a calcified plaque score of 0 had a change in management compared to CCTA alone.
Suggested decrease in risk of cardiac events based on average LDL-C decrease of 18.7 mg/dL for those with change in management.¹
Heartflow Is the Proven Choice for Plaque
With the DECIDE Registry, Heartflow continues to deliver high-quality evidence, proving again our commitment to transforming how CAD is managed — one insight, one patient, and one decision at a time.
Download DECIDE Data SheetJoin the Movement Toward Smarter, Preventive Care
Whether you're looking to improve treatment plans, outcomes, or gain greater confidence in how you care for your patients, Heartflow Plaque Analysis is the new standard in preventive CAD management. DECIDE what’s right for your patients today.